

# YEAR-END REPORT

## Q4 2025

OCTOBER - DECEMBER



# Summary of the period

## "Forward momentum despite winds blowing in opposite directions"

Net sales during the fourth quarter amounted to SEK 38,676 (57,804) thousand, corresponding to a decrease in sales of 33% compared to the last quarter of 2024. The operating profit amounted to SEK 7,553 (16,763) thousand. Net sales for the full year 2025 amounted to SEK 168,116 (179,451) thousand, corresponding to a decrease in sales of 6.3% compared to the full year 2024. The operating profit amounted to SEK 41,037 (45,490) thousand, with a strong operating cash flow of SEK 64,601 (35,173) thousand, up 84% compared to the full year 2024.

### Significant events January to December 2025

- I-Tech AB signed a supply and license agreement with major Asian-based paint company
- Annual General Meeting elected Tomas Bergdahl, Philip Chaabane, Raouf Kattan, Chatarina Schneider, Tomas Tedgren, and Staffan Asplund as Board Directors
- The Standing Committee on Biocidal Products extended Selektope's current EU market approval by one year to allow completion of the ongoing re-registration process.
- I-Tech AB was awarded DI Gasell company status by Dagens Industri for the second year in a row.
- The European Commission drafted an implementation act proposing the non-renewal of the approval of Medetomidine (Selektope®) under the EU Biocidal Products Regulation (BPR).
- I-Tech AB and Guangdong Havey Advanced Materials Technology Co., Ltd. signed MoU to collaborate on the development of next-generation antifouling materials.
- Board member Raouf Kattan has, at his own request, decided to step down from the Board as he concludes his assignments and enters retirement, effective 31 March 2026.
- The board proposes an ordinary dividend of SEK 1.25 (1.00) per share, corresponding to 45% of the net profit for the year.

### Significant events after the end of the period

- No significant events occurred after the period.

## Financial summary

All amounts in kSEK	2025 Oct-Dec	2024 Oct-Dec	2025 Jan-Dec	2024 Jan-Dec
Net sales	38,676	57,804	168,116	179,451
Operating result	7,553	16,763	41,037	45,490
EBITDA	9,558	18,821	49,027	53,713
Net result	6,383	14,299	33,194	39,013
Operating cash flow	12,611	6,173	64,601	35,173
Equity at end of period	174,386	157,388	174,386	157,388
Cash and cash equivalents at end of period	148,160	100,164	148,160	100,164

# CEO Comments

2025 has been a year of mixed financial results and significant progress in shaping a more diversified and resilient I-Tech. Most customers continued to develop positively, while some faced a challenging year.

Overall, our sales volume grew by 3%, but total sales in SEK contracted by 6% to 168 (179) million as the average USD/SEK exchange rate depreciated by 7.8 % year-on-year. Our total gross profit increased by 1.5% to SEK 96 (95) million due to margin improvement measures, and stable sales prices. The operating profit (EBIT) for the year was SEK 41 (45) million, down 10% year-on-year.

Accelerating geopolitical uncertainty continued to impact shipping. However, macro indicators for both newbuild and maintenance remain in positive territory for I-Tech. Overall charter rates (measured by the ClarkSea index) increased by 7% in 2025. Although tariffs affected the timing and direction of trade flows, seaborne trade grew by 1.1% in volume (2.2% in 2024). Shipyard output increased (6% in CGT terms), with 52% of the volume coming from China, 28% from South Korea, and 12% from Japan. In 2026, the output is expected to continue growing by 15%. Newbuild contracting activity recovered during the second half but remained down 27% year-on-year, still 34% above the ten-year trend.

Q4 marked our fourth-best quarter on record for volume. Three new coating products with Selektape, complying with upcoming legislation (low biocide content), were launched in Korea during the quarter. However, it will take time before the new products contribute significant added volume.

The relative development among accounts differed substantially in 2025. CMP continues to develop positively, with total volume increasing by 21%. Kansai Paint grew by 109%, PPG by 126%, and Jotun by 108%, while the sizeable customer that previously reported financial constraints reduced volume offtake for the calendar year by two thirds. The geographical split of sales in 2025 was 37% to Korea, 31% to Japan, 26% to China, 4% to the rest of Asia, and 2% to Europe. China is a key growth market and grew offtake by 96% year-on-year.



## Selektape's Regulatory Approval in the EU

In December, the European Commission announced a draft implementation act proposing the non-renewal of the approval of Medetomidine (Selektape®) under the EU Biocidal Products Regulation (BPR). I-Tech AB firmly disagrees with this proposal - a view shared by a broad coalition of stakeholders - and continues to engage in dialogue to influence the outcome. Voting on the implementation act is expected during the first half of 2026. Preparations to challenge a potential negative outcome, including legal actions, are nearly complete.

## Business Development

Business development progressed steadily, with several new partnership discussions underway. One area under development is sustainable binders, and an MoU with Havey was signed in December. Binders and biocides are two of the most important technologies for high-performing antifouling coatings and represent a large portion of the raw material value in customer formulations. To cope with the workload of building a more diversified and resilient I-Tech capability investment is now being made.

The team is preparing to welcome several new permanent members during the first half of 2026 and looks forward to another exciting year.

Markus Jönsson

CEO I-Tech

# Business and structure


I-Tech AB (publ) is a biotech company active in the materials and chemical sector. The company develops and sells the product Selektope, an active ingredient to counteract marine growth used in coating systems for the commercial shipping industry. The company's business is primarily focused on antifouling coatings. The company's customers are the leading global marine coating companies. Asia is the dominant market.

I-Tech owns the rights to Selektope and has the necessary manufacturing expertise. The company was founded in 2000 as a spin-off company from the University of Gothenburg and Chalmers University of Technology, and is now located at GoCo Health Innovation City in Mölndal, just south of Gothenburg in Sweden.

Since the listing on Nasdaq First North Growth in 2018, the company has grown both customer-

wise and financially. The market is dominated by nine major paint companies where nearly all work actively with the company's technology. Seven of them are commercially active and the others are in the development stage. Thanks to a continued stable financial position, clear investments have been made in the core business. Within the regulatory area, the geographical coverage is increased step by step at the same time as upgrades and renewals of existing approvals are required at regular intervals. The company also invests in research and development in line with the strategy of offering a higher level of knowledge about Selektope's formulation properties in antifouling coatings. The continuous improvement work has also led to an increased delivery capacity and efficiency in the production chain.

## Rolling twelve-month turnover



Despite a year marked by both tailwinds and headwinds, I-Tech managed to maintain a steady course forward. The underlying business continued to develop positively, with increasing volumes and several customer relationships strengthening, even though a larger customer reduced their purchases. At the same time, net sales were pressured by a weaker USD/SEK, resulting in a slightly lower outcome than the previous year.

Overall, 2025 demonstrates a robust operation with strong resilience, solid commercial development, and a clear position for continued growth in the coming years.

# Other information

## Share information

During 2025, the warrant program Series 2022/2025 was ended, fully subscribed and the share capital was increased by SEK 178,640 divided into 89,320 shares. Total share capital as of June 30, 2025 amounts to SEK 23,995,554 divided into 11,997,777 shares. The ratio value of all the shares amounts to SEK 2 and they have equal rights in the company's assets and profit/loss. I-Tech's shares were listed on the Nasdaq First North Growth Market at Nasdaq Stockholm as of 29 May 2018.

As of 30 December, the number of shareholders amounted to 3,046 (2,430). With a closing price for the share on 30 December of SEK 52.2 (58.0), the company's market capitalisation amounted to SEK 626 (691) million.

## Risk factors

The company's risks are primarily related to the market development of Selektope, production risks related to partners' production and production capacity, as well as risks in regulatory permissions, other intangible assets and product development. For a more detailed description of significant risks and uncertainty factors, please see I-Tech's prospectus, which was published in conjunction with the public offering and the company's annual report for 2024.

## Certified Adviser

I-Tech has engaged DNB Carnegie Investment Bank as the Certified Adviser on First North at Nasdaq Stockholm.

## Long-term incentive programs

In May, the Annual General Meeting resolved on a new long-term incentive program, Series 2025/2028, for management and other personnel in the form of warrants with a term of three years. The program includes a total of

356,800 warrants with a maximum dilution of approximately 2.9%. A total of 52,150 have been issued and paid. The exercise price is SEK 126.40 per share. Each warrant gives the right to acquire one share.

## Audit review

This report has not been reviewed by the company's auditors.

## List of stakeholders

The list of stakeholders shows the status in the company as of 30 December 2025

## Largest owners

Owner	No. of shares	Share capital %
Pomona-gruppen	1,756,417	14.64%
Handelsbanken Funds	791,340	6.60%
Swedbank Robur	785,000	6.54%
Futur pension	747,729	6.23%
Second Swedish National Pension Fund	643,400	5.36%
NEA Partners	624,000	5.20%
Avanza pension	594,285	4.95%
Unionen	475,000	3.96%
Stefan Sedersten incl. Companies	441,330	3.68%
Nordnet pension	401,696	3.35%
Alcur fonder	329,082	2.74%
Tind Asset Management	321,087	2.68%
Lannebo Asset Management	287,543	2.40%
Göran Källebo	150,000	1.25%
Montanaro	129,520	1.08%
Others	3,520,348	29.34%
<b>Total shares</b>	<b>11,997,777</b>	<b>100.00%</b>

# Financial information

## Turnover and profit/loss

Sales for the period amounted to SEK 38,676 (57,804) thousand, corresponding to a 33% decrease in revenue compared with the 129% increase in the previous year. The period continues to be characterized by the fact that the second largest customer is underperforming relative to expectations and the previous year. The comparative figures are also still affected by the USD/SEK exchange rate, which has decreased by 13% compared with the previous year; adjusted for currency effects, the revenue decline therefore amounts to 23%.

The gross margin remains strong for the period at 57% (54%), in line with the previous period and as a result of the investments made in this area.

Other external costs continue to show a slight increase. Business development efforts are ongoing, and the company's EU BPR re-registration continues to drive high expenses. Due to the continued strengthening of the Swedish krona, the majority of other operating expenses are attributable to foreign exchange losses. As a result of the earnings trend during the year - and thus a lower bonus outcome - personnel costs decrease by nearly 20% for the period.

As a consequence of the lower gross profit, despite overall lower operating expenses, operating profit is weakened. EBITDA amounts to SEK 9,558 (18,821) thousand, with a lower operating margin, although still at a high level, of 25% (33%).

## Cash flow

Despite the lower operating profit, the company delivered improved cash conversion, resulting in an increase in cash flow from operating activities to SEK 12,611 (6,173). Of this, the result account for SEK 9,437 (20,551) thousand and working capital for SEK 3,174 (-14,738) thousand.

During the period, I-Tech invested SEK 185 (273) thousand in fixed assets.

In total, this results in a cash flow for the period of SEK 12,426 (5,900) thousand.

## Financial summary

Cash and cash equivalents at the end of the period amounted to SEK 148,160 (100,164) thousand, and equity totaled SEK 174,386 (157,388) thousand. The changes in cash, cash equivalents and equity during the period are directly attributable to the company's profit and other operating-related movements.

## Principles of preparation

The interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). The accounting principles are described in more detail in the company's annual report for the financial year 2024.

# Upcoming financial reports

7 May 2026	Interim report, quarter 1
21 August 2026	Interim report, quarter 2
16 October 2026	Interim report, quarter 3

# Income statement

Amounts in kSEK	2025 Oct-Dec	2024 Oct-Dec	2025 Jan-Dec	2024 Jan-Dec
Operating income etc.				
Net sales	38,676	57,804	168,116	179,451
Other operating income	266	1,424	2,348	2,325
	<b>38,942</b>	<b>59,228</b>	<b>170,464</b>	<b>181,776</b>
Cost of goods sold	-16,575	-26,516	-72,270	-84,228
Other external costs	-6,482	-6,140	-25,589	-22,185
Personnel expenses	-5,397	-6,720	-17,679	-17,767
Depreciations amortizations and impairments	-2,005	-2,058	-7,990	-8,223
Other operating expenses	-930	-1,031	-5,899	-3,883
	<b>-31,389</b>	<b>-42,465</b>	<b>-129,427</b>	<b>-136,286</b>
<b>Operating profit</b>	<b>7,553</b>	<b>16,763</b>	<b>41,037</b>	<b>45,490</b>
Financial items				
Interest income and similar items	443	1,287	1,741	3,724
Interest expense and similar items	59	-	-940	-38
	<b>502</b>	<b>1,287</b>	<b>801</b>	<b>3,686</b>
<b>Result after financial items</b>	<b>8,055</b>	<b>18,050</b>	<b>41,838</b>	<b>49,176</b>
Tax on result from the year	-1,672	-3,751	-8,644	-10,163
<b>NET RESULT</b>	<b>6,383</b>	<b>14,299</b>	<b>33,194</b>	<b>39,013</b>

# Balance sheet

Amounts in kSEK	2025 Dec-31	2024 Dec-31
<b>ASSETS</b>		
Intangible assets	15,590	22,731
Tangible assets	1,954	2,394
Total fixed assets	17,544	25,125
Inventory	9,436	9,869
Short-term receivables	18,594	37,956
Cash and bank balances	148,160	100,164
Total current assets	176,190	147,989
<b>Total assets</b>	<b>193,734</b>	<b>173,114</b>
<b>EQUITY AND LIABILITIES</b>		
Share capital	23,996	23,817
Restricted equity	1,562	1,545
Unrestricted equity	115,634	93,013
Result	33,194	39,013
Total equity	174,386	157,388
Short-term liabilities	19,348	15,726
Total liabilities	19,348	15,726
<b>Total equity and liabilities</b>	<b>193,734</b>	<b>173,114</b>

# Cash-flow analysis

Amounts in kSEK	2025 Oct-Dec	2024 Oct-Dec	2025 Jan-Dec	2024 Jan-Dec
<b>Operating activities</b>				
Operating result	7,553	16,763	41,037	45,490
Adjustments for non-cash items	2,005	2,058	7,990	8,223
Interest received	607	1,644	1,631	3,806
Interest paid	59	-	-940	-38
Income tax paid/received	-787	86	-810	28
<b>Changes in working capital</b>				
Change in inventories	4,020	1,613	433	-5,589
Change in operating receivables	2,979	-10,150	19,472	-15,409
Change in operating liabilities	-3,825	-5,841	-4,212	-1,338
<b>Cash flow from operating activities</b>	<b>12,611</b>	<b>6,173</b>	<b>64,601</b>	<b>35,173</b>
<b>Investment activities</b>				
Investments in non-current assets	-185	-273	-409	-408
<b>Cash flow from investment activities</b>	<b>-185</b>	<b>-28</b>	<b>-409</b>	<b>-408</b>
<b>Financing activities</b>				
Dividend to shareholders	-	-	-20,840	-17,863
New issue	-	-	4,644	-
<b>Cash flow from financing activities</b>	<b>-</b>	<b>-</b>	<b>-16,196</b>	<b>-17,863</b>
<b>The period's cash flow</b>	<b>12,426</b>	<b>5,900</b>	<b>47,996</b>	<b>16,902</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>135,734</b>	<b>94,264</b>	<b>100,164</b>	<b>83,262</b>
<b>Cash and cash equivalents at end period</b>	<b>148,160</b>	<b>100,164</b>	<b>148,160</b>	<b>100,164</b>
Adjustments for non-cash items				
Depreciation and amortizations	2,005	2,058	7,990	8,223
Other items not affecting cash flow	-	-	-	-
	<b>2,005</b>	<b>2,052</b>	<b>7,990</b>	<b>8,223</b>

# Equity changes

All amounts in kSEK	Restricted equity			Unrestricted equity		Total equity
	Share capital	Statutory reserve	Development expense fund	Share premium reserve	Other unrestricted equity	
2024-01-01	23,817	753	729	143,276	-32,337	136,238
Dividend to shareholders	-	-	-	-	-17,863	-17,863
Capitalization of development expenses	-	-	63	-	-63	-
Net result for the year	-	-	-	-	39,013	39,013
<b>2024-12-31</b>	<b>23,817</b>	<b>753</b>	<b>792</b>	<b>143,276</b>	<b>-11,250</b>	<b>157,388</b>
2025-01-01	23,817	753	792	143,276	-11,250	157,388
Dividend to shareholders	-	-	-	-	-20,840	-20,840
New issue	179	-	-	3,760	705	4,644
Capitalization of development expenses	-	-	17	-	-17	-
Net result for the period	-	-	-	-	33,194	33,194
<b>2025-12-31</b>	<b>23,996</b>	<b>753</b>	<b>809</b>	<b>147,036</b>	<b>1,792</b>	<b>174,386</b>

# Financial ratios

Amounts in kSEK	2025 Oct-Dec	2024 Oct-Dec	2025 Jan-Dec	2024 Jan-Dec
Turnover growth %	-33%	129%	-6%	48%
Gross margin %	57%	54%	57%	53%
Operating margin %	20%	29%	24%	25%
Net profit margin %	17%	25%	20%	22%
Solidity	90%	91%	90%	91%
Cash liquidity	862%	878%	862%	878%
Return on average total capital	3%	8%	18%	24%
Return on average total equity	4%	10%	20%	27%
Average of outstanding shares	11,997,777	11,908,457	11,957,889	11,908,457
Outstanding shares end of period	11,997,777	11,908,457	11,997,777	11,908,457
Result per share	0.5	1.2	2.8	3.3
Result per share fully diluted	0.5	1.2	2.8	3.3
Equity per share	14.5	13.2	14.5	14.6
Equity per share fully diluted	14.5	13.1	14.5	13.1
Dividend per share	-	-	1.8	1.5

## DEFINITIONS OF KEY FIGURES

### Net sales growth

The percentage increase in sales for the past period compared with the corresponding previous period.

### Gross margin

Gross profit for the period in relation to the period's net sales.

### Gross profit

Net sales of the period decreased by raw materials and supplies.

### Operating margin

Operating profit for the period in relation to the period's net sales.

### Profit margin

Profit for the period in relation to the period's net sales.

### Solidity

Shareholders' equity as a percentage of total assets.

### Cash liquidity

Current assets, excluding inventories, in relation to current liabilities, without adjustment for proposed dividend.

### Return on average total capital

Net profit for the period, as a percentage of average total capital.

### Return on average total equity

Net profit for the period, as a percentage of average shareholders' equity.

### Result per share

Profit for the period divided by the average number of outstanding shares during the year.

### Equity per share

Total equity divided by the number of shares at the end of the period.

The board and the managing director  
assures that the interim report provides a fair overview  
of the Company's position and results

Mölndal 5 February 2026

Philip Chaabane, Chairman of the board  
Tomas Tedgren, Member of the board  
Chatarina Schneider, Member of the board  
Tomas Bergdahl, Member of the board  
Raouf Kattan, Member of the board  
Staffan Asplund, Member of the board  
Markus Jönsson, Chief Executive Officer

### Address

I-Tech AB  
GoCo Health Innovation City  
Förändringens gata 10  
SE 431 53 Mölndal  
Tel: 010-3303999  
org.nr: 556585-9682

[www.i-tech.se](http://www.i-tech.se)

### Contact

Magnus Henell, CFO  
Tel: +46(0)73 910 37 03  
[magnus.henell@i-tech.se](mailto:magnus.henell@i-tech.se)

Markus Jönsson, CEO  
Tel: +46(0) 72 977 96 25  
[markus.jonsson@i-tech.se](mailto:markus.jonsson@i-tech.se)